ES3068271T3 - Thrb receptor agonist compound and preparation method and use thereof - Google Patents
Thrb receptor agonist compound and preparation method and use thereofInfo
- Publication number
- ES3068271T3 ES3068271T3 ES25157448T ES25157448T ES3068271T3 ES 3068271 T3 ES3068271 T3 ES 3068271T3 ES 25157448 T ES25157448 T ES 25157448T ES 25157448 T ES25157448 T ES 25157448T ES 3068271 T3 ES3068271 T3 ES 3068271T3
- Authority
- ES
- Spain
- Prior art keywords
- thrb
- preparation
- receptor agonist
- agonist compound
- thrα
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/30—Phthalazines
- C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811527414.4A CN111320609A (zh) | 2018-12-13 | 2018-12-13 | 一种THRβ受体激动剂化合物及其制备方法和用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES3068271T3 true ES3068271T3 (en) | 2026-05-28 |
Family
ID=71071432
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES25157448T Active ES3068271T3 (en) | 2018-12-13 | 2019-12-12 | Thrb receptor agonist compound and preparation method and use thereof |
| ES19896475T Active ES3064255T3 (en) | 2018-12-13 | 2019-12-12 | Thrb receptor agonist compound and preparation method and use thereof |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES19896475T Active ES3064255T3 (en) | 2018-12-13 | 2019-12-12 | Thrb receptor agonist compound and preparation method and use thereof |
Country Status (30)
| Country | Link |
|---|---|
| US (6) | US11084802B2 (enExample) |
| EP (3) | EP4529954A3 (enExample) |
| JP (3) | JP7532371B2 (enExample) |
| KR (2) | KR20250133486A (enExample) |
| CN (4) | CN121081472A (enExample) |
| AR (1) | AR117694A1 (enExample) |
| AU (2) | AU2019398339C1 (enExample) |
| BR (1) | BR112021010871A2 (enExample) |
| CA (1) | CA3120880A1 (enExample) |
| CL (1) | CL2021001521A1 (enExample) |
| CO (1) | CO2021008817A2 (enExample) |
| DK (2) | DK4574821T3 (enExample) |
| ES (2) | ES3068271T3 (enExample) |
| FI (2) | FI3893889T3 (enExample) |
| HR (2) | HRP20260358T1 (enExample) |
| IL (3) | IL283362B2 (enExample) |
| LT (2) | LT3893889T (enExample) |
| MA (2) | MA71903B1 (enExample) |
| MD (2) | MD3893889T2 (enExample) |
| MX (2) | MX2021006908A (enExample) |
| MY (1) | MY207657A (enExample) |
| PE (2) | PE20252338A1 (enExample) |
| PL (2) | PL3893889T3 (enExample) |
| PT (2) | PT3893889T (enExample) |
| RS (2) | RS67892B1 (enExample) |
| SG (1) | SG11202106194TA (enExample) |
| SI (2) | SI3893889T1 (enExample) |
| SM (1) | SMT202600270T1 (enExample) |
| TW (3) | TWI837244B (enExample) |
| WO (1) | WO2020123827A1 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2795450T3 (es) | 2012-09-17 | 2020-11-23 | Madrigal Pharmaceuticals Inc | Procedimiento para sintetizar análogos de hormonas tiroideas y polimorfos de los mismos |
| ES3029158T3 (en) | 2018-06-12 | 2025-06-23 | Xizang Haisco Pharmaceutical Co Ltd | Thyroid hormone receptor agonists and uses thereof |
| TWI884745B (zh) | 2018-10-12 | 2025-05-21 | 美商拓臻股份有限公司 | 甲狀腺素受體β促效劑化合物 |
| CN121081472A (zh) | 2018-12-13 | 2025-12-09 | 拓臻股份有限公司 | 一种THRβ受体激动剂化合物及其制备方法和用途 |
| WO2020227549A1 (en) | 2019-05-08 | 2020-11-12 | Aligos Therapeutics, Inc. | MODULATORS OF THR-β AND METHODS OF USE THEREOF |
| WO2020228577A1 (zh) * | 2019-05-10 | 2020-11-19 | 深圳微芯生物科技股份有限公司 | 一种哒嗪酮衍生物及其应用 |
| WO2020239076A1 (zh) * | 2019-05-29 | 2020-12-03 | 南京明德新药研发有限公司 | 作为甲状腺素受体-β激动剂的哒嗪酮类衍生物及其应用 |
| CA3154488A1 (en) | 2019-08-23 | 2021-03-04 | Terns Pharmaceuticals, Inc. | Thyroid hormone receptor beta agonist compounds |
| CA3154391A1 (en) | 2019-09-12 | 2021-03-18 | Terns Pharmaceuticals, Inc. | Thyroid hormone receptor beta agonist compounds |
| WO2021121210A1 (zh) * | 2019-12-16 | 2021-06-24 | 江苏恒瑞医药股份有限公司 | 并环类衍生物、其制备方法及其在医药上的应用 |
| WO2021231646A1 (en) * | 2020-05-13 | 2021-11-18 | Terns Pharmaceuticals, Inc. | Combination treatment of liver disorders |
| PE20231096A1 (es) | 2020-08-25 | 2023-07-18 | Lilly Co Eli | Polimorfos de un inhibidor de ssao |
| WO2022053028A1 (zh) * | 2020-09-10 | 2022-03-17 | 南京明德新药研发有限公司 | 1,2,4-三嗪-3,5(2h,4h)-二酮类化合物及其应用 |
| EP4215524A4 (en) * | 2020-09-17 | 2024-10-02 | Sunshine Lake Pharma Co., Ltd. | COMPOUND AS A THYROID HORMONE BETA RECEPTOR AGONIST AND USES OF THE COMPOUND |
| CA3195960A1 (en) * | 2020-10-23 | 2022-04-28 | Madrigal Pharmaceuticals, Inc. | Process for the preparation of 6-(4-nitro-phenoxy)-2h-pyridazin-3-one and 6-(4-amino-phenoxy)-2h-pyridazin-3-one derivatives as intermediates of thyroid hormone analogues |
| KR20230123928A (ko) | 2020-11-06 | 2023-08-24 | 알리고스 테라퓨틱스 인코포레이티드 | 갑상선 호르몬 수용체 베타(tr-베타) 작용제로서의 비사이클릭 피리다지논 |
| CN114437034A (zh) * | 2020-11-06 | 2022-05-06 | 深圳微芯生物科技股份有限公司 | 一种酞嗪类化合物的可药用盐、晶型及其制备方法 |
| CN114591300A (zh) * | 2020-12-04 | 2022-06-07 | 南京圣和药业股份有限公司 | 作为THRβ激动剂的杂环化合物及其应用 |
| CN116925045B (zh) * | 2020-12-15 | 2026-05-01 | 中国科学院上海药物研究所 | 甲状腺素受体β选择性激动剂化合物、其药物组合物和用途 |
| CN114685450B (zh) | 2020-12-30 | 2026-06-16 | 昆药集团股份有限公司 | 2-吡啶酮类衍生物及其制备方法和在医药上的应用 |
| JP2024510935A (ja) * | 2021-03-03 | 2024-03-12 | ターンズ・ファーマシューティカルズ・インコーポレイテッド | 甲状腺ホルモン受容体ベータアゴニスト化合物 |
| MX2024005647A (es) * | 2021-11-11 | 2024-05-24 | Terns Pharmaceuticals Inc | Tratamiento de trastornos hepaticos con un agonista del thr-\03b2. |
| AU2022387121A1 (en) | 2021-11-11 | 2024-06-20 | Terns Pharmaceuticals, Inc. | Combination of a ssao inhibitor and thr-beta agonist for use in the treatment of liver disorders |
| CN119137113A (zh) * | 2022-02-10 | 2024-12-13 | 马德里加尔制药公司 | THRβ类似物及其用途 |
| CN118146217A (zh) | 2022-12-07 | 2024-06-07 | 昆药集团股份有限公司 | 一种甲状腺激素β受体激动剂、晶型、制备方法和用途 |
| US20260216110A1 (en) * | 2022-12-26 | 2026-07-30 | National University Corporation Tokai National Higher Education And Research System | COMPOUND USEFUL AS THYROID HORMONE RECEPTOR ß-SELECTIVE THYROID HORMONE ANALOG |
| PE20252787A1 (es) | 2023-04-07 | 2025-12-22 | Terns Pharmaceuticals Inc | Combinacion que comprende un agonista de thr-beta y un agonista de glp-1r para su uso en el tratamiento de un trastorno hepatico o una enfermedad cardiometabolica |
| WO2025162405A1 (zh) * | 2024-02-01 | 2025-08-07 | 罗群 | 苯酚类衍生物及其医药用途 |
| US12377104B1 (en) | 2024-02-06 | 2025-08-05 | Madrigal Pharmaceuticals, Inc. | Methods for treating a fatty liver disease |
| WO2025245216A1 (en) * | 2024-05-22 | 2025-11-27 | Terns Pharmaceuticals, Inc. | Treatment of liver disorders with a thr-beta agonist |
| US20260102403A1 (en) * | 2024-10-11 | 2026-04-16 | Aligos Therapeutics, Inc. | Oral formulations of thr-beta agonist |
| WO2026092583A1 (en) | 2024-10-30 | 2026-05-07 | Ascletis Pharma (China) Co., Limited | Thr-beta modulators, alone or in combination with glp-1r\gipr\gcgr modulators for the treatment of metabolic diseases and alopecia areata diseases |
Family Cites Families (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4197307A (en) | 1977-04-12 | 1980-04-08 | Ciba-Geigy Corporation | 2-Alkylthio-, 2-alkylsulphinyl- and 2-alkylsulfonyl-6-phenylbenzimidazoles as anthelmintic agents |
| EP0377903A3 (de) | 1989-01-09 | 1991-07-17 | Bayer Ag | Substituierte Hexahydro-1,2,4-triazindione, Verfahren zu ihrer Herstellung, Zwischenprodukte dafür und ihre Verwendung |
| US6787652B1 (en) | 1999-09-30 | 2004-09-07 | Pfizer, Inc. | 6-Azauracil derivatives as thyroid receptor ligands |
| DE60020786T2 (de) | 1999-09-30 | 2006-03-23 | Pfizer Products Inc., Groton | 6-Azauracilderivate als Liganden der Thyroidrezeptoren |
| GB0015205D0 (en) | 2000-06-21 | 2000-08-09 | Karobio Ab | Bioisosteric thyroid receptor ligands and method |
| WO2002051805A1 (de) | 2000-12-27 | 2002-07-04 | Bayer Aktiengesellschaft | Indol-derivate |
| CA2473162A1 (en) | 2002-01-30 | 2003-08-07 | Kissei Pharmaceutical Co., Ltd. | Novel thyroid hormone receptor ligand, medicinal compositions containing the same and use thereof |
| WO2003094845A2 (en) | 2002-05-08 | 2003-11-20 | Bristol-Myers Squibb Company | Pyridine-based thyroid receptor ligands |
| GB0327319D0 (en) | 2003-11-24 | 2003-12-24 | Pfizer Ltd | Novel pharmaceuticals |
| US7572799B2 (en) | 2003-11-24 | 2009-08-11 | Pfizer Inc | Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors |
| FR2882750B1 (fr) | 2005-03-03 | 2007-05-11 | Pierre Fabre Medicament Sa | Derives de 1,2,4-triazines, leur preparation et leur application en therapeutique humaine |
| GB0513692D0 (en) | 2005-07-04 | 2005-08-10 | Karobio Ab | Novel pharmaceutical compositions |
| ATE480524T1 (de) * | 2005-07-21 | 2010-09-15 | Hoffmann La Roche | Pyridazinonderivate als schilddrüsenhormon- rezeptoragonisten |
| GB0608724D0 (en) | 2006-05-03 | 2006-06-14 | Karobio Ab | Novel Pharmaceutical Compositions |
| GB0610322D0 (en) | 2006-05-24 | 2006-07-05 | Karobio Ab | Novel pharmaceutical compositions |
| WO2008130637A1 (en) | 2007-04-18 | 2008-10-30 | New York University | Hydrazide compounds as thyroid hormone receptor modulators and uses thereof |
| SI2170403T1 (sl) | 2007-06-27 | 2014-07-31 | Quark Pharmaceuticals, Inc. | Sestavki in postopki za inhibicijo ekspresije pro-apoptotskih genov |
| TW200906823A (en) | 2007-07-16 | 2009-02-16 | Lilly Co Eli | Compounds and methods for modulating FXR |
| US8076334B2 (en) | 2007-09-20 | 2011-12-13 | Hoffmann-La Roche Inc. | Prodrugs of thyroid hormone analogs |
| FR2933979B1 (fr) | 2008-07-15 | 2012-08-24 | Pf Medicament | Derives de triazines et uraciles, leur preparation et leur application en therapeutique humaine |
| KR101396606B1 (ko) | 2009-04-20 | 2014-05-16 | 미쓰비시 타나베 파마 코퍼레이션 | 신규 갑상선 호르몬 β 수용체 작동약 |
| WO2011038207A1 (en) | 2009-09-25 | 2011-03-31 | Metabasis Therapeutics, Inc. | Phosphorus-containing thyroid hormone receptor agonists and methods of use |
| JP2011114768A (ja) | 2009-11-30 | 2011-06-09 | Panasonic Corp | 複合無線装置 |
| EA023521B1 (ru) | 2011-11-14 | 2016-06-30 | Сефалон, Инк. | ПРОИЗВОДНЫЕ УРАЦИЛА В КАЧЕСТВЕ ИНГИБИТОРОВ AXL И c-MET КИНАЗЫ |
| CN103130723B (zh) | 2011-11-30 | 2015-01-14 | 成都地奥制药集团有限公司 | 一种多聚(adp-核糖)聚合酶抑制剂 |
| CN102898377B (zh) * | 2012-02-14 | 2016-01-20 | 南京圣和药业股份有限公司 | 一类酞嗪酮衍生物及其用途 |
| ES2795450T3 (es) | 2012-09-17 | 2020-11-23 | Madrigal Pharmaceuticals Inc | Procedimiento para sintetizar análogos de hormonas tiroideas y polimorfos de los mismos |
| CA2944139C (en) | 2014-04-11 | 2020-11-03 | Cymabay Therapeutics, Inc. | Treatment of nafld and nash |
| CN107074823B (zh) | 2014-09-05 | 2021-05-04 | 基因泰克公司 | 治疗性化合物及其用途 |
| CN105477636B (zh) | 2015-10-16 | 2019-09-17 | 厦门大学 | 使用阿维菌素及其衍生物治疗代谢疾病的方法 |
| TWI757266B (zh) | 2016-01-29 | 2022-03-11 | 美商維它藥物有限責任公司 | ＲＯＲ－γ調節劑 |
| MX2018011813A (es) | 2016-03-28 | 2019-01-24 | Intercept Pharmaceuticals Inc | Medicina obtenida mediante la combinacion de agonista fxr y arb. |
| PL3435996T3 (pl) | 2016-03-31 | 2025-07-28 | Genfit | Elafibranor do zastosowania w leczeniu pierwotnego zapalenia dróg żółciowych |
| MX2018014024A (es) | 2016-05-25 | 2019-08-29 | Akarna Therapeutics Ltd | Terapias de combinación con moduladores del receptor x farnesoide (fxr). |
| WO2018027892A1 (en) | 2016-08-12 | 2018-02-15 | Eli Lilly And Company | Amino pyrimidine ssao inhibitors |
| MX394463B (es) | 2016-10-18 | 2025-03-19 | Madrigal Pharmaceuticals Inc | Métodos para tratar trastornos del hígado o trastornos lipídicos con un agonista de thr-beta. |
| CA3041169A1 (en) | 2016-10-19 | 2018-04-26 | Boehringer Ingelheim International Gmbh | Combinations comprising an ssao/vap-1 inhibitor and a sglt2 inhibitor, uses thereof |
| WO2018103624A1 (zh) | 2016-12-06 | 2018-06-14 | 江苏恒瑞医药股份有限公司 | 一种κ阿片受体激动剂在制备治疗法尼醇X受体激动剂引起的瘙痒的药物中的用途 |
| WO2018109607A1 (en) | 2016-12-16 | 2018-06-21 | Pfizer Inc. | Glp-1 receptor agonists and uses thereof |
| JP7618384B2 (ja) | 2017-02-21 | 2025-01-21 | ジェンフィ | Ｐｐａｒアゴニストとｆｘｒアゴニストとの組合せ |
| SG11201907673YA (en) | 2017-03-13 | 2019-09-27 | Genfit | Pharmaceutical compositions for combination therapy |
| WO2018170173A1 (en) | 2017-03-15 | 2018-09-20 | Metacrine, Inc. | Farnesoid x receptor agonists and uses thereof |
| CA3058542A1 (en) | 2017-04-18 | 2018-10-25 | Genfit | Combination comprising a ppar agonist such as elafibranor and an acetyl-coa carboxylase (acc) inhibitor |
| WO2018208707A1 (en) | 2017-05-08 | 2018-11-15 | Neurovia, Inc. | Methods and compositions for treating demyelinating diseases |
| US20210121493A1 (en) | 2017-07-25 | 2021-04-29 | Cedars-Sinai Medical Center | Methods for treating liver diseases |
| SG11202000748TA (en) | 2017-08-25 | 2020-03-30 | Genfit | Non-invasive diagnostic of non-alcoholic fatty liver diseases, non-alcoholic steatohepatitis and/or liver fibrosis |
| WO2019053235A1 (en) | 2017-09-15 | 2019-03-21 | Genfit | NON-INVASIVE DIAGNOSIS OF NON ALCOHOLIC LIVER DISEASES, NON ALCOHOLIC STHEATHEPATITIS AND / OR HEPATIC FIBROSIS |
| EP3684954B1 (en) | 2017-09-18 | 2025-11-26 | Genfit | Non-invasive diagnostic of non-alcoholic fatty liver diseases, non-alcoholic steatohepatitis and/or liver fibrosis |
| US11168079B2 (en) | 2017-11-01 | 2021-11-09 | Bristol-Myers Squibb Company | Alkene compounds as farnesoid x receptor modulators |
| US20200340060A1 (en) | 2017-11-13 | 2020-10-29 | Gilead Sciences, Inc. | Compositions and methods for identifying and treating liver diseases and monitoring treatment outcomes |
| CN109574995B (zh) | 2018-01-23 | 2020-07-24 | 深圳市塔吉瑞生物医药有限公司 | 取代的哒嗪酮化合物 |
| KR20210002573A (ko) | 2018-04-24 | 2021-01-08 | 주식회사 피에이치파마 | 간 질환에 호중구 엘라스타제 저해제의 사용 |
| ES3029158T3 (en) | 2018-06-12 | 2025-06-23 | Xizang Haisco Pharmaceutical Co Ltd | Thyroid hormone receptor agonists and uses thereof |
| WO2020041741A1 (en) | 2018-08-24 | 2020-02-27 | Terns, Inc. | Thyroid hormone receptor beta agonist compounds |
| US11541745B2 (en) | 2018-08-24 | 2023-01-03 | Plastic Omnium Advanced Innovation And Research | Assembly for a fluid tank comprising a baffle and a fluid transfer line passing through the baffle |
| EP3844156A4 (en) | 2018-08-30 | 2022-06-08 | Terns Pharmaceuticals, Inc. | TREATMENT OF LIVER DISEASES |
| US20220047553A1 (en) | 2018-09-18 | 2022-02-17 | Metacrine, Inc. | Farnesoid x receptor agonists for the treatment of disease |
| NZ773110A (en) | 2018-09-18 | 2024-11-29 | Terns Inc | Compounds for treating certain leukemias |
| TWI884745B (zh) | 2018-10-12 | 2025-05-21 | 美商拓臻股份有限公司 | 甲狀腺素受體β促效劑化合物 |
| CN119552152A (zh) | 2018-10-12 | 2025-03-04 | 益方生物科技(上海)股份有限公司 | 甲状腺激素受体激动剂 |
| CN121081472A (zh) | 2018-12-13 | 2025-12-09 | 拓臻股份有限公司 | 一种THRβ受体激动剂化合物及其制备方法和用途 |
| WO2020131578A2 (en) | 2018-12-17 | 2020-06-25 | Mitopower Llc | Nicotinyl riboside compounds and their uses |
| CN111484481A (zh) | 2019-01-26 | 2020-08-04 | 察略盛医药科技(上海)有限公司 | 哒嗪酮类衍生物、其制备方法及其在医药上的用途 |
| CN119431265A (zh) | 2019-02-21 | 2025-02-14 | 南京瑞捷医药科技有限公司 | 一种作为甲状腺激素受体激动剂的化合物 |
| WO2020227549A1 (en) | 2019-05-08 | 2020-11-12 | Aligos Therapeutics, Inc. | MODULATORS OF THR-β AND METHODS OF USE THEREOF |
| WO2020228577A1 (zh) | 2019-05-10 | 2020-11-19 | 深圳微芯生物科技股份有限公司 | 一种哒嗪酮衍生物及其应用 |
| WO2020239076A1 (zh) | 2019-05-29 | 2020-12-03 | 南京明德新药研发有限公司 | 作为甲状腺素受体-β激动剂的哒嗪酮类衍生物及其应用 |
| TW202114672A (zh) | 2019-07-23 | 2021-04-16 | 瑞士商諾華公司 | 使用fxr促效劑的肝臟疾病之組合治療 |
| CN112409340B (zh) | 2019-08-21 | 2022-03-18 | 海创药业股份有限公司 | 卤素取代的苯醚类化合物及其用途 |
| CA3154488A1 (en) | 2019-08-23 | 2021-03-04 | Terns Pharmaceuticals, Inc. | Thyroid hormone receptor beta agonist compounds |
| CA3154391A1 (en) | 2019-09-12 | 2021-03-18 | Terns Pharmaceuticals, Inc. | Thyroid hormone receptor beta agonist compounds |
| WO2021121210A1 (zh) | 2019-12-16 | 2021-06-24 | 江苏恒瑞医药股份有限公司 | 并环类衍生物、其制备方法及其在医药上的应用 |
| WO2021231644A1 (en) | 2020-05-13 | 2021-11-18 | Terns Pharmaceuticals, Inc. | Combination treatment of liver disorders |
| WO2021231646A1 (en) | 2020-05-13 | 2021-11-18 | Terns Pharmaceuticals, Inc. | Combination treatment of liver disorders |
| US20220135540A1 (en) | 2020-10-15 | 2022-05-05 | Eli Lilly And Company | Polymorphs of an fxr agonist |
| CN114437034A (zh) | 2020-11-06 | 2022-05-06 | 深圳微芯生物科技股份有限公司 | 一种酞嗪类化合物的可药用盐、晶型及其制备方法 |
| MX2023008365A (es) | 2021-01-14 | 2023-10-04 | Enyo Pharma | Efecto sinérgico de un agonista de fxr e ifn para el tratamiento de infección por hbv. |
| JP2024510935A (ja) | 2021-03-03 | 2024-03-12 | ターンズ・ファーマシューティカルズ・インコーポレイテッド | 甲状腺ホルモン受容体ベータアゴニスト化合物 |
| US20240239761A1 (en) | 2021-03-19 | 2024-07-18 | Medshine Discovery Inc. | Bicyclic phenol compounds and use thereof |
| AU2022387121A1 (en) | 2021-11-11 | 2024-06-20 | Terns Pharmaceuticals, Inc. | Combination of a ssao inhibitor and thr-beta agonist for use in the treatment of liver disorders |
| MX2024005647A (es) | 2021-11-11 | 2024-05-24 | Terns Pharmaceuticals Inc | Tratamiento de trastornos hepaticos con un agonista del thr-\03b2. |
| WO2023220404A1 (en) | 2022-05-13 | 2023-11-16 | Terns Pharmaceuticals, Inc. | Treatment of non-alcoholic steatohepatitis |
-
2018
- 2018-12-13 CN CN202511225496.7A patent/CN121081472A/zh active Pending
- 2018-12-13 CN CN201811527414.4A patent/CN111320609A/zh active Pending
-
2019
- 2019-12-12 EP EP25157450.5A patent/EP4529954A3/en active Pending
- 2019-12-12 AR ARP190103650A patent/AR117694A1/es unknown
- 2019-12-12 SM SM20260270T patent/SMT202600270T1/it unknown
- 2019-12-12 HR HRP20260358TT patent/HRP20260358T1/hr unknown
- 2019-12-12 BR BR112021010871-8A patent/BR112021010871A2/pt unknown
- 2019-12-12 PT PT198964751T patent/PT3893889T/pt unknown
- 2019-12-12 PE PE2025001790A patent/PE20252338A1/es unknown
- 2019-12-12 EP EP19896475.1A patent/EP3893889B8/en active Active
- 2019-12-12 PL PL19896475.1T patent/PL3893889T3/pl unknown
- 2019-12-12 CA CA3120880A patent/CA3120880A1/en active Pending
- 2019-12-12 ES ES25157448T patent/ES3068271T3/es active Active
- 2019-12-12 PE PE2021000858A patent/PE20211788A1/es unknown
- 2019-12-12 TW TW108145594A patent/TWI837244B/zh active
- 2019-12-12 FI FIEP19896475.1T patent/FI3893889T3/fi active
- 2019-12-12 JP JP2021533640A patent/JP7532371B2/ja active Active
- 2019-12-12 MX MX2021006908A patent/MX2021006908A/es unknown
- 2019-12-12 DK DK25157448.9T patent/DK4574821T3/da active
- 2019-12-12 IL IL283362A patent/IL283362B2/en unknown
- 2019-12-12 MD MDE20211031T patent/MD3893889T2/ro unknown
- 2019-12-12 WO PCT/US2019/066013 patent/WO2020123827A1/en not_active Ceased
- 2019-12-12 KR KR1020257028884A patent/KR20250133486A/ko active Pending
- 2019-12-12 EP EP25157448.9A patent/EP4574821B8/en active Active
- 2019-12-12 RS RS20260307A patent/RS67892B1/sr unknown
- 2019-12-12 SI SI201931033T patent/SI3893889T1/sl unknown
- 2019-12-12 MA MA71903A patent/MA71903B1/fr unknown
- 2019-12-12 SG SG11202106194TA patent/SG11202106194TA/en unknown
- 2019-12-12 PT PT251574489T patent/PT4574821T/pt unknown
- 2019-12-12 SI SI201931032T patent/SI4574821T1/sl unknown
- 2019-12-12 AU AU2019398339A patent/AU2019398339C1/en active Active
- 2019-12-12 MY MYPI2021002740A patent/MY207657A/en unknown
- 2019-12-12 LT LTEPPCT/US2019/066013T patent/LT3893889T/lt unknown
- 2019-12-12 LT LTEP25157448.9T patent/LT4574821T/lt unknown
- 2019-12-12 CN CN202310453989.0A patent/CN116444498B/zh active Active
- 2019-12-12 FI FIEP25157448.9T patent/FI4574821T3/fi active
- 2019-12-12 MD MDE20250525T patent/MD4574821T2/ro unknown
- 2019-12-12 KR KR1020217021249A patent/KR102905557B1/ko active Active
- 2019-12-12 IL IL310699A patent/IL310699B2/en unknown
- 2019-12-12 MA MA54471A patent/MA54471B1/fr unknown
- 2019-12-12 ES ES19896475T patent/ES3064255T3/es active Active
- 2019-12-12 RS RS20260315A patent/RS67879B1/sr unknown
- 2019-12-12 TW TW113107718A patent/TWI899867B/zh active
- 2019-12-12 HR HRP20260475TT patent/HRP20260475T1/hr unknown
- 2019-12-12 CN CN201980081797.3A patent/CN113194958B/zh active Active
- 2019-12-12 DK DK19896475.1T patent/DK3893889T3/da active
- 2019-12-12 TW TW114133235A patent/TWI925761B/zh active
- 2019-12-12 PL PL25157448.9T patent/PL4574821T3/pl unknown
- 2019-12-12 US US16/712,301 patent/US11084802B2/en active Active
-
2020
- 2020-09-04 US US17/013,314 patent/US11034676B2/en active Active
-
2021
- 2021-06-10 MX MX2024003295A patent/MX2024003295A/es unknown
- 2021-06-10 CL CL2021001521A patent/CL2021001521A1/es unknown
- 2021-07-02 CO CONC2021/0008817A patent/CO2021008817A2/es unknown
-
2023
- 2023-05-10 US US18/315,291 patent/US12338232B2/en active Active
-
2024
- 2024-07-31 JP JP2024124269A patent/JP2024174860A/ja active Pending
-
2025
- 2025-02-13 US US19/052,553 patent/US12365669B2/en active Active
- 2025-02-13 US US19/052,557 patent/US12459926B2/en active Active
- 2025-03-05 AU AU2025201590A patent/AU2025201590A1/en active Pending
- 2025-09-04 US US19/319,446 patent/US20260001867A1/en active Pending
- 2025-11-06 IL IL324507A patent/IL324507A/en unknown
- 2025-12-04 JP JP2025229427A patent/JP2026035823A/ja active Pending